benefit from b-lymphocyte depletion using the anti-cd20 antibody rituximab in chronic fatigue syndrome. a double-blind and placebo-controlled study受益于淋巴球减少使用anti-cd20抗体美罗华在慢性疲劳综合症。.pdfVIP

Benefit from B-Lymphocyte Depletion Using the Anti- CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study 1 1,2 1 3 4 1 Øystein Fluge *, Ove Bruland , Kristin Risa , Anette Storstein , Einar K. Kristoffersen , Dipak Sapkota , 3 1,5 3 1,5 Halvor Næss , Olav Dahl , Harald Nyland , Olav Mella 1 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway, 2 Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway, 3 Department of Neurology, Haukeland University Hospital, Bergen, Norway, 4 Department of Immunology and Transfusion Medicine, Haukeland University Hospital, and The Gade Institute, University of Bergen, Bergen, Norway, 5 Institute of Internal Medicine, Section of Oncology, University of Bergen, Bergen, Norway Abstract Background: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the anti-CD20 antibody Rituximab, which demonstrated significant clinical response in three CFS patients. Methods and Findings: In this double-blind, placebo-controlled phase II study (NC, 30 CFS patients were randomised to either Rituximab 500 mg/m2 or saline, given twice two weeks apart, with follow-up for 12 months. Xenotropic murine leukemia virus-related virus (XMRV) was not detected in any of the patients. The responses generally affected all CFS symptoms. Major or moderate